Navigation Links
Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
Date:10/25/2011

tive Disease Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 27

Table 16: Neurodegenerative Disease Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 27

Table 17: Neurodegenerative Disease Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 28

Table 18: Neurodegenerative Disease Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 28

Table 19: Neurodegenerative Disease Market, Top Five Countries of Europe, Treatment Usage Pattern (thousand), 2002-2010 29

Table 20: Neurodegenerative Disease Market, Top Five Countries of Europe, Treatment Usage Patterns (Thousand), 2010-2017 30

Table 21: Neurodegenerative Disease Market, Japan, Revenue ($m), 2002-2010 31

Table 22: Neurodegenerative Disease Market, Japan, Revenue Forecasts ($m), 2010-2017 31

Table 23: Neurodegenerative Disease Market, Japan, Annual Cost of Treatment ($), 2010-2017 32

Table 24: Neurodegenerative Disease Market, Japan, Annual Cost of Treatment ($), 2010-2017 32

Table 25: Neurodegenerative Disease Market, Japan, Treatment Usage Patterns (thousand), 2002-2010 33

Table 26: Neurodegenerative Disease Market, Japan, Treatment Usage Patterns (thousand), 2010-2017 34

Table 27: Neurodegenerative Disease Market, Alzheimer's Disease, FDA Approved Cholinesterase Inhibitors, 2010 36

Table 28: Neurodegenerative Disease Market, Alzheimer's Disease, Global Revenue ($bn), 2002-2010 37

Table 29: Neurodegenerative Disease Market, Alzheimer's Disease, Global Revenue Forecasts ($bn), 2010-2017 37

Table 30: Neurodegenerative Disease Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2010 38

Table 31: Neurodegenerative Disease Market, Alzheimer's Disease, Revenue by Country ($m), 2010-2017 39

Table 32: Neurodegenerative Disease Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2010 40

Table 33: N
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders
2. Gene Therapy Slows Progression of Fatal Neurodegenerative Disease in Children
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
4. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
5. Global Neurodegenerative Drugs Industry
6. US Patent Granted for a New Family of Heat Shock Protein 90 (Hsp90) Inhibitors for the Treatment of Cancer and Neurodegenerative Indications
7. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
10. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
11. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 /PRNewswire-iReach/ -- The global microbial ... products, methods, applications, end users, and geographies. Genotypic ... the microbial identification market. This favorable growth is ... test) and the time required for microbial identification ... advancements. Furthermore, genotypic methods have high applications in ...
(Date:7/29/2014)... Calif., July 29, 2014 Amgen (NASDAQ: ... second quarter of 2014. Key results include: , ... 8 percent product sales growth driven by strong performance ... ® (carfilzomib), Prolia ® (denosumab) and XGEVA ... percent to $2.37, driven by higher revenues and a ...
(Date:7/29/2014)...  Express Scripts Holding Company (Nasdaq: ESRX ... Express Scripts stockholders of $515.2 million, or $0.67 per ... in Table 4, was $1.23 for the second quarter. ... serve our clients with scale, alignment and innovative solutions to ... outcomes of our members," stated George Paz, chairman and chief ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... GARDEN CITY, New York, Oct. 7 ... Merkin recognize and congratulate seniors enrolled with HCP, IPA ... concern, health care reform, directly to members of Congress, ... http://www.newscom.com/cgi-bin/prnh/20091007/LA89266 ) , Dr. John Gastright, Senior ...
... , WALTHAM, Mass., Oct. 7 Nova Biomedical Corporation, ... that the company,s independent, wholly owned subsidiary, Sanvita CBGM, ... Sanvita, Inc., a subsidiary of CCS Medical, Inc. ... through this transaction, Nova,s Consumer Blood Glucose Monitoring (CBGM) ...
Cached Medicine Technology:HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC 2HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC 3Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc. 2
(Date:7/29/2014)... 29, 2014 Daily Gossip reveals in its ... a holistic nutritional and functional medicine practitioner, who spent years ... problem. , Karen suffered from leaky gut, too, so this ... develop this unique treatment. , Karen Brimeyer decided to ... from all around the world. The author of the Leaky ...
(Date:7/29/2014)... July 29, 2014 DailyGossip.org reveals in ... actually is a new method of naturally overcoming sciatica, ... of the new method ensure sufferers that the cure ... recommendations. , The new method is described as ... overcome sciatica with an 8 minutes per day treatment ...
(Date:7/29/2014)... For numerous women from all over the world, finding love, ... quite hard. Well, the author of the Make Him Desire ... help all these women. This is the formula that will ... attention every day. , Daily Gossip reveals in its ... Carter who published a unique eBook to detail it. ...
(Date:7/29/2014)... 29, 2014 Winter is here down ... afternoon in Sydney’s central business district. That is, until ... costume transformed the otherwise ordinary day into a celebration—a ... are ardent advocates of The Truth About Drugs, a ... Scientology . They woke up the city with a ...
(Date:7/29/2014)... July 29, 2014 Parker Waichman LLP, ... of victims injured by defective drugs and medical devices, ... by plaintiffs in Canada who allege that they were ... with the low testosterone injection Delatestryl (Court File ... 2014 in the Ontario Superior Court of Justice. , ...
Breaking Medicine News(10 mins):Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3
... reducing weight and increasing exercise cut the risk of ... sugar are known to be at increased risk of ... complications, it would be very useful if there was ... disease. ,Researchers for the Diabetes Prevention Programme ...
... food meals may be quick and easy, but no matter ... fat. Now there is new reason to restrict the junk ... Nestel, of melbourne's Baker Medical Research Institute, fed 10 volunteers ... butter, whole milk and ice cream (the meal delivered 50 ...
... that Women who smoke while pregnant are 60 percent to ... a baby with a cleft lip or palate. The risk ... that a mother-to-be smokes each day, even after factors like ... finding, based on the largest-ever examination of cleft lip and ...
... was initially lauded as a major breakthrough for women ... their// prescription because of the drug's rigid dosing instructions: ... minutes before eating, and downed with plenty of water. ... indigestion. ,So scientists tried giving women a week's ...
... composition and anti-oxidant content are associated with ... derived from diabetic patients.//Researchers designed a study ... from patients with diabetes mellitus to normoglycemic ... effects of dietary beta-carotene supplementation on LDL ...
... yet another good reason to exercise regularly. We know that ... our risk of heart disease and stroke,// and it even ... also good for reducing our risk of ovarian cancer. ... very appropriate. That makes it all the more important to ...
Cached Medicine News:
... The BAK Vista implant is the ... clear and confident fusion assessment with the ... design. The BAK Vista System is ... This allows for unobstructed radiologic visualization, ...
... (Western Blot): The Genetic Systems HIV-1 Western ... the detection of antibodies to HIV-1. The solid ... HIV-1 grown in the CEM cell line. Use ... of HLA Class ll antigens, helps reduce cross ...
... VERSANT HIV-1 RNA Assay (bDNA) delivers unmatched precision ... you're providing physicians with viral load values they ... end and at other critical decision points - ... you need more reasons to choose VERSANT HIV ...
... The Procleix System has added a ... nation's blood supply. It utilizes innovative technologies ... a unique nucleic acid amplification technique called ... simultaneously detect the presence of HIV-1 and ...
Medicine Products: